Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine.

Knudsen ML, Mbewe-Mvula A, Rosario M, Johansson DX, Kakoulidou M, Bridgeman A, Reyes-Sandoval A, Nicosia A, Ljungberg K, Hanke T, Liljeström P.

J Virol. 2012 Apr;86(8):4082-90. doi: 10.1128/JVI.06535-11. Epub 2012 Feb 8.

2.

Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques.

Rosario M, Borthwick N, Stewart-Jones GB, Mbewe-Mvula A, Bridgeman A, Colloca S, Montefiori D, McMichael AJ, Nicosia A, Quakkelaar ED, Drijfhout JW, Melief CJ, Hanke T.

AIDS. 2012 Jan 28;26(3):275-84. doi: 10.1097/QAD.0b013e32834ed9b2.

PMID:
22095198
3.

Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen.

Knudsen ML, Ljungberg K, Tatoud R, Weber J, Esteban M, Liljeström P.

PLoS One. 2015 Feb 2;10(2):e0117042. doi: 10.1371/journal.pone.0117042. eCollection 2015.

4.

Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice.

Ondondo B, Brennan C, Nicosia A, Crome SJ, Hanke T.

Vaccine. 2013 Nov 12;31(47):5594-601. doi: 10.1016/j.vaccine.2013.06.068. Epub 2013 Jul 2.

5.

Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1.

Nordström EK, Forsell MN, Barnfield C, Bonin E, Hanke T, Sundström M, Karlsson GB, Liljeström P.

J Gen Virol. 2005 Feb;86(Pt 2):349-54.

PMID:
15659754
6.

Characterization of T-cell responses to conserved regions of the HIV-1 proteome in BALB/c mice.

Ondondo B, Abdul-Jawad S, Bridgeman A, Hanke T.

Clin Vaccine Immunol. 2014 Nov;21(11):1565-72. doi: 10.1128/CVI.00587-14. Epub 2014 Sep 17.

7.

A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).

Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, Kroidl A, Shaffer D, Eller LA, Kibaya R, Eller MA, Schindler KB, Schuetz A, Millard M, Kroll J, Dally L, Hoelscher M, Bailer R, Cox JH, Marovich M, Birx DL, Graham BS, Michael NL, de Souza MS, Robb ML.

J Infect Dis. 2010 Feb 15;201(4):600-7. doi: 10.1086/650299.

8.

Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.

Hayton EJ, Rose A, Ibrahimsa U, Del Sorbo M, Capone S, Crook A, Black AP, Dorrell L, Hanke T.

PLoS One. 2014 Jul 9;9(7):e101591. doi: 10.1371/journal.pone.0101591. eCollection 2014.

9.

Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques.

Luckay A, Sidhu MK, Kjeken R, Megati S, Chong SY, Roopchand V, Garcia-Hand D, Abdullah R, Braun R, Montefiori DC, Rosati M, Felber BK, Pavlakis GN, Mathiesen I, Israel ZR, Eldridge JH, Egan MA.

J Virol. 2007 May;81(10):5257-69. Epub 2007 Feb 28.

10.

Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.

Kanagavelu SK, Snarsky V, Termini JM, Gupta S, Barzee S, Wright JA, Khan WN, Kornbluth RS, Stone GW.

Vaccine. 2012 Jan 17;30(4):691-702. doi: 10.1016/j.vaccine.2011.11.088. Epub 2011 Dec 4.

11.

Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.

Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, Tang A, Chen M, Huang L, Harris V, Freed DC, Wilson KA, Dubey S, Zhu DM, Nawrocki D, Mach H, Troutman R, Isopi L, Williams D, Hurni W, Xu Z, Smith JG, Wang S, Liu X, Guan L, Long R, Trigona W, Heidecker GJ, Perry HC, Persaud N, Toner TJ, Su Q, Liang X, Youil R, Chastain M, Bett AJ, Volkin DB, Emini EA, Shiver JW.

J Virol. 2003 Jun;77(11):6305-13.

12.

Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques.

Hirao LA, Wu L, Khan AS, Satishchandran A, Draghia-Akli R, Weiner DB.

Vaccine. 2008 Jan 17;26(3):440-8. Epub 2007 Nov 8.

PMID:
18082294
13.

Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.

Megede JZ, Otten GR, Doe B, Liu H, Srivastava R, Greer C, Legg H, Tang T, Polo JM, Donnelly JJ, Ulmer JB, Barnett SW.

Vaccine. 2006 Apr 5;24(15):2755-63. Epub 2006 Jan 19.

PMID:
16460840
14.

Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine.

Hanke T, Barnfield C, Wee EG, Agren L, Samuel RV, Larke N, Liljeström P.

J Gen Virol. 2003 Feb;84(Pt 2):361-8.

PMID:
12560568
15.

Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.

Abaitua F, Rodríguez JR, Garzón A, Rodríguez D, Esteban M.

Virus Res. 2006 Mar;116(1-2):11-20. Epub 2005 Oct 7.

PMID:
16214252
16.

Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.

Bakari M, Aboud S, Nilsson C, Francis J, Buma D, Moshiro C, Aris EA, Lyamuya EF, Janabi M, Godoy-Ramirez K, Joachim A, Polonis VR, Bråve A, Earl P, Robb M, Marovich M, Wahren B, Pallangyo K, Biberfeld G, Mhalu F, Sandström E.

Vaccine. 2011 Oct 26;29(46):8417-28. doi: 10.1016/j.vaccine.2011.08.001. Epub 2011 Aug 22.

17.

Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes.

Mann JF, McKay PF, Fiserova A, Klein K, Cope A, Rogers P, Swales J, Seaman MS, Combadiere B, Shattock RJ.

J Virol. 2014 Jun;88(12):6959-69. doi: 10.1128/JVI.00183-14. Epub 2014 Apr 9.

18.

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.

Hanke T, Goonetilleke N, McMichael AJ, Dorrell L.

J Gen Virol. 2007 Jan;88(Pt 1):1-12. Review. Erratum in: J Gen Virol. 2008 Feb;89(Pt 2):609. Goonetilleke, Nilu [added].

PMID:
17170430
19.

A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.

Shephard E, Burgers WA, Van Harmelen JH, Monroe JE, Greenhalgh T, Williamson C, Williamson AL.

AIDS Res Hum Retroviruses. 2008 Feb;24(2):207-17. doi: 10.1089/aid.2007.0206.

PMID:
18240963
20.

Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques.

Rosario M, Hopkins R, Fulkerson J, Borthwick N, Quigley MF, Joseph J, Douek DC, Greenaway HY, Venturi V, Gostick E, Price DA, Both GW, Sadoff JC, Hanke T.

J Virol. 2010 Jun;84(12):5898-908. doi: 10.1128/JVI.02607-09. Epub 2010 Apr 7.

Supplemental Content

Support Center